Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required?

Eur Respir J. 2013 Oct;42(4):1148-50. doi: 10.1183/09031936.00184312.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amikacin / adverse effects
  • Amikacin / blood*
  • Amikacin / therapeutic use*
  • Antitubercular Agents / adverse effects
  • Antitubercular Agents / blood*
  • Antitubercular Agents / therapeutic use*
  • Audiology
  • Drug Monitoring / methods*
  • Female
  • Hearing Loss / chemically induced
  • Humans
  • Kidney / drug effects
  • Male
  • Retrospective Studies
  • Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

  • Antitubercular Agents
  • Amikacin